Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva Pharmaceuticals to $38 from $35 with an Overweight rating. Following Teva Pharmaceuticals’ Q4 2025 report, the firm updated its financial model and expressed continued confidence in the stock’s current valuation. A day before that, Scotiabank raised the price target on Teva Pharmaceuticals to $40 from $35 while maintaini ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited's share was trading at $33.07 as of January 28th. TEVA’s trailing and forward P/E were 27.45 and 11.70 respectively according to Yahoo Finance. Jim Cramer Comments On Eli Lilly (LLY)'s Shares After Pfizer CEO's Remarks Teva Pharmaceutical Industries Limited develops, manufactures, markets, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other ju ...

Core Viewpoint - Teva Pharmaceutical Industries Limited is considered one of the best healthcare stocks to buy for 2026, with analysts optimistic about its growth potential despite some revenue headwinds [1][2]. Financial Performance - Teva reported strong Q4 2025 results, with earnings per share (EPS) of $0.96, surpassing the forecast of $0.65, and revenue of $4.71 billion, exceeding expectations of $4.33 billion, aided by a $500 million milestone payment from Sanofi [3]. - However, the company projected lower revenue for 2026, estimating between $16.4 billion and $16.8 billion, along with adjusted EPS of $2.57 to $2.77, reflecting a significant impact from lost sales of its generic Revlimid due to increased competition [3]. Growth Drivers - Teva's innovative portfolio is a key growth driver, with Austedo generating $725 million in U.S. sales in Q4, marking a 40% year-over-year increase. The combined revenue from Austedo, Ajovy, and Uzedy reached $3.1 billion in 2025 and is expected to grow to up to $3.6 billion in 2026 [4]. - Analysts highlight pipeline catalysts, including a potential FDA decision on Olanzapine LAI, which could unlock a $3 billion sales opportunity, supporting Teva's growth narrative [1][2]. Market Position - Teva is recognized as a global leader in generic and specialty medicines, focusing on the development, manufacturing, and marketing of drugs across various therapeutic areas, including central nervous system, respiratory, and oncology [5].

Company Overview - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the world's largest generic drug makers, producing medical products including generic pills, inhalers, and treatments for conditions like migraines and cancer [2]. Stock Performance - The stock of Teva has experienced a significant turnaround, gaining nearly 400% from its 2022 lows following a leadership change with Richard Francis taking over at the beginning of 2023 [1]. - Over the past 12 months, Teva's stock has increased by 54% [1]. - Despite a quarterly report that exceeded expectations, the company's full-year forecast was perceived as slightly light, leading to an initial stock drop of 9% after the announcement [1]. - The stock stabilized after the conference call and finished the day up more than 2% [1].

Core Viewpoint - Teva Pharmaceutical Industries is experiencing a positive outlook due to strong financial performance and an increased price target from Scotiabank, indicating potential growth opportunities for investors [2][4][5] Financial Performance - Teva reported a significant increase in its fourth-quarter profit, driven by strong sales of branded drugs and a milestone payment for treatments related to ulcerative colitis and Crohn's disease [2][5] - The company's current market capitalization is approximately $37.31 billion, reflecting its substantial presence in the pharmaceutical industry [4] Stock Performance - The current stock price of TEVA is $32.54, which has seen a decrease of 2.03% with a change of $0.68 [3][5] - TEVA's stock has fluctuated between a low of $32.19 and a high of $33.43 today, with the highest price over the past year being $33.43 and the lowest at $12.47, indicating volatility and growth potential [3][5] Analyst Ratings - Scotiabank maintains an "Outperform" rating for TEVA and has raised its price target from $35 to $40, reflecting an optimistic outlook for the company's future performance [2][5] - The trading volume for TEVA today is 2,763,304 shares, indicating active investor interest [4]

Key Takeaways TEVA posted Q4 adjusted EPS of 96 cents and $4.71B in revenues, with both beating consensus estimates.TEVA's results were driven by a $500M Sanofi milestone and strong branded drug sales, led by Austedo.TEVA guided 2026 revenues of $16.4-$16.8B with continued momentum across Austedo, Ajovy and Uzedy.Teva Pharmaceutical Industries (TEVA) reported fourth-quarter 2025 adjusted earnings of 96 cents per share, which comprehensively beat the Zacks Consensus Estimate of 65 cents. Adjusted earnings ro ...

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Greenlight Capital’s investment strategy focuses on constructing a bottom-up portfolio comprising undervalued long positions and overvalued short positions, while also including a macro book to hedge risks and capture insights. The Partnership returned 9.0% (net) in 2025 compared to 17.9% for the S&P 500 index. In contrast, it returned 8.5% in Q4, compared to 2 ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, according to Benzinga Pro.Revenues increased 11% year-over-year in U.S. dollars or 9% in local currency.The increase was mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) and from higher revenues from key innovative products, par ...

Teva Stock Slides On Guidance Surprise Despite Fourth-Quarter Beat | Investor's Business DailyANALYSIS: [AI Bubble Or Boom? Wall Street Weighs In]Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience.---Teva stock tumbled Wednesday on surprisingly light guidance for 2026 following a decisive fourth-quarter beat. For the year, Teva Pharmaceutical (TEVA) expects to earn an adjusted $2.57 to $2.77 per share on $1 ...